Clinical Edge Journal Scan

Psoriatic arthritis management should target both clinical and biochemical inflammation


 

Key clinical point: In patients with psoriatic arthritis (PsA ), clinical inflammation monitored by swollen joint counts (SJC) and biochemical inflammation monitored by C-reactive protein (CRP) level, have a direct effect on structural progression.

Major finding: Progression was significantly higher in patients with active vs. inactive time-averaged SJC (odds ratio [OR] 1.24; P = .016) and time-averaged CRP (OR 6.08; P = .036). Progression was greatest in presence of both clinical and biochemical inflammation and lowest in absence of both ( P = .05).

Study details: Findings are secondary analysis of patient data from the IMPACT 2 trial, including 145 patients with PsA.

Disclosures: The study did not report any source of funding. The authors declared serving as associate editor or receiving grants and honoraria from several sources.

Source: Borst C et al. RMD Open. 2021;7:e002038 (Dec 8). Doi: 10.1136/rmdopen-2021-002038.

Recommended Reading

Serious infection hospitalizations have declined in patients with PsA
MDedge Rheumatology
Guselkumab’s efficacy, safety confirmed in patients with psoriatic arthritis and prior TNFi exposure
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: PsA December 2021
MDedge Rheumatology
Upadacitinib (Rinvoq) gains psoriatic arthritis as second FDA-approved indication
MDedge Rheumatology
New option for flares in pustular psoriasis
MDedge Rheumatology
Spesolimab speeds lesion clearance in generalized pustular psoriasis
MDedge Rheumatology
Case series show no consensus on treatment for palmoplantar pustulosis, generalized pustular psoriasis
MDedge Rheumatology
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
MDedge Rheumatology
Discontinuing TNF inhibitors may not be required in PsA patients receiving BNT162b2 SARS-CoV-2 vaccine
MDedge Rheumatology
PsA: Upadacitinib shows similar benefits as monotherapy or in combination with nbDMARDs
MDedge Rheumatology